An update on therapeutic opportunities offered by cancer glycolytic metabolism.

Almost all invasive cancers, regardless of tissue origin, are characterized by specific modifications of their cellular energy metabolism. In fact, a strong predominance of aerobic glycolysis over oxidative phosphorylation (Warburg effect) is usually associated with aggressive tumour phenotypes. This metabolic shift offers a survival advantage to cancer cells, since they may continue to produce energy and anabolites even when they are exposed to either transient or permanent hypoxic conditions. Moreover, it ensures a high production rate of glycolysis intermediates, useful as building blocks for fast cell proliferation of cancer cells. This peculiar metabolic profile may constitute an ideal target for therapeutic interventions that selectively hit cancer cells with minimal residual systemic toxicity. In this review we provide an update about some of the most recent advances in the discovery of new bioactive molecules that are able to interfere with cancer glycolysis.

[1]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[2]  G. Giannaccini,et al.  Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) , 2011 .

[3]  W. Marston Linehan,et al.  Targeting Cancer Metabolism , 2012, Clinical Cancer Research.

[4]  John L Cleveland,et al.  Targeting lactate metabolism for cancer therapeutics. , 2013, Journal of Clinical Investigation.

[5]  K. Soliman,et al.  High-Throughput Screening to Identify Plant Derived Human LDH-A Inhibitors , 2013, European journal of medicinal plants.

[6]  L. Cantley,et al.  Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. , 2012, Chemistry & biology.

[7]  Meng Zhang,et al.  Detection of Protein–Small Molecule Binding Using a Self-Referencing External Cavity Laser Biosensor , 2014, 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[8]  B. Dwarakanath,et al.  Radiosensitization by 2-deoxy-D-glucose and 6-aminonicotinamide involves activation of redox sensitive ASK1-JNK/p38MAPK signaling in head and neck cancer cells. , 2012, Free radical biology & medicine.

[9]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[10]  A. Galina,et al.  Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. , 2009, The Biochemical journal.

[11]  BinQing Wei,et al.  Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase. , 2013, Bioorganic & medicinal chemistry letters.

[12]  Eyal Gottlieb,et al.  Serine is a natural ligand and allosteric activator of pyruvate kinase M2 , 2012, Nature.

[13]  A. Kinghorn,et al.  Constituents of an extract of Cryptocarya rubra housed in a repository with cytotoxic and glucose transport inhibitory effects. , 2014, Journal of natural products.

[14]  R. Wahl,et al.  Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. , 2012, Translational research : the journal of laboratory and clinical medicine.

[15]  Taro Hitosugi,et al.  Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. , 2012, Cancer cell.

[16]  R. Aft,et al.  2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. , 2003, Cancer research.

[17]  O. Becker,et al.  1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2012, Bioorganic & medicinal chemistry letters.

[18]  L. Chin,et al.  Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.

[19]  Hui Li,et al.  The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications , 2014, International journal of cancer.

[20]  J. Trent,et al.  Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer , 2013, Molecular Cancer Therapeutics.

[21]  T. Seyfried,et al.  Cancer as a metabolic disease: implications for novel therapeutics , 2013, Carcinogenesis.

[22]  Lucia Kerti,et al.  Effects of Resveratrol on Memory Performance, Hippocampal Functional Connectivity, and Glucose Metabolism in Healthy Older Adults , 2014, The Journal of Neuroscience.

[23]  Juliana Camacho-Pereira,et al.  3-Bromopyruvate inhibits calcium uptake by sarcoplasmic reticulum vesicles but not SERCA ATP hydrolysis activity. , 2012, The international journal of biochemistry & cell biology.

[24]  K. Kinoshita,et al.  Phenolic compounds from Cryptocarya konishii: their cytotoxic and tyrosine kinase inhibitory properties , 2010, Journal of Natural Medicines.

[25]  E. Giovannetti,et al.  N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. , 2011, European journal of medicinal chemistry.

[26]  S. Ravera,et al.  Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II , 2013, Scientific Reports.

[27]  Xiaozhuo Chen,et al.  Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells. , 2013, Bioorganic & medicinal chemistry letters.

[28]  R. Ramanathan,et al.  Covalent binding of 4-hydroxy-2-nonenal to lactate dehydrogenase decreases NADH formation and metmyoglobin reducing activity. , 2014, Journal of agricultural and food chemistry.

[29]  E. Seront,et al.  Antitumor Activity of 7-Aminocarboxycoumarin Derivatives, a New Class of Potent Inhibitors of Lactate Influx but Not Efflux , 2014, Molecular Cancer Therapeutics.

[30]  E. Giovannetti,et al.  Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. , 2011, Journal of medicinal chemistry.

[31]  P. Hergenrother,et al.  Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. , 2013, Organic & biomolecular chemistry.

[32]  J. Vera,et al.  Noncompetitive blocking of human GLUT1 hexose transporter by methylxanthines reveals an exofacial regulatory binding site. , 2012, American journal of physiology. Cell physiology.

[33]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[34]  Paul D. Smith,et al.  Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[35]  M. Maekawa,et al.  Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. , 1988, Clinica chimica acta; international journal of clinical chemistry.

[36]  A. Merlo,et al.  Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death , 2008, Clinical Cancer Research.

[37]  V. Muronetz,et al.  Structure‐Based Design of Small‐Molecule Ligands of Phosphofructokinase‐2 Activating or Inhibiting Glycolysis , 2013, ChemMedChem.

[38]  D. Sabatini,et al.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.

[39]  Chao Xu,et al.  Crystal structure of the human glucose transporter GLUT1 , 2014, Nature.

[40]  Yan Liu,et al.  Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms. , 2010, Cancer letters.

[41]  W. Denny,et al.  Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). , 2014, Bioorganic & medicinal chemistry.

[42]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[43]  S. Kulp,et al.  Development of a novel class of glucose transporter inhibitors. , 2012, Journal of medicinal chemistry.

[44]  K. Parnell,et al.  Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth , 2013, Molecular Cancer Therapeutics.

[45]  Martin G Pomper,et al.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.

[46]  Jon Winter,et al.  Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. , 2012, Journal of medicinal chemistry.

[47]  P. Dell'antone,et al.  Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. , 2006, Life sciences.

[48]  R. Loffroy,et al.  3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. , 2010, Current pharmaceutical biotechnology.

[49]  J. Vera,et al.  Resolution of the direct interaction with and inhibition of the human GLUT1 hexose transporter by resveratrol from its effect on glucose accumulation. , 2013, American journal of physiology. Cell physiology.

[50]  G. Giannaccini,et al.  Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5. , 2011, Bioorganic & medicinal chemistry letters.

[51]  J. Milner,et al.  Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways , 2014, Oncogenesis.

[52]  Xiaozhuo Chen,et al.  Novel inhibitors of basal glucose transport as potential anticancer agents. , 2010, Bioorganic & medicinal chemistry letters.

[53]  J. Lee,et al.  Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells , 2008, Journal of bioenergetics and biomembranes.

[54]  K. Parnell,et al.  Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). , 2014, Bioorganic & medicinal chemistry letters.

[55]  O. Feron,et al.  Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments , 2011, Disease Models & Mechanisms.

[56]  Darren R. Williams,et al.  A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes. , 2013, ACS chemical biology.

[57]  D. Khaitan,et al.  Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line , 2006, Cancer biology & therapy.

[58]  A. Galina.  Mitochondria: 3-bromopyruvate vs. mitochondria? A small molecule that attacks tumors by targeting their bioenergetic diversity. , 2014, The international journal of biochemistry & cell biology.

[59]  Shiyong Wu,et al.  A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.

[60]  R. Moreno-Sánchez,et al.  Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation , 2012, Archives of Toxicology.

[61]  Jung-Hwan Yoon,et al.  Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis , 2011, Acta Pharmacologica Sinica.

[62]  V. Ganapathy,et al.  Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3‐bromopyruvate , 2009, Cancer.

[63]  P. Hergenrother,et al.  Dual Targeting of the Warburg Effect with a Glucose‐Conjugated Lactate Dehydrogenase Inhibitor , 2013, Chembiochem : a European journal of chemical biology.

[64]  G. Cheon,et al.  Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma , 2007, Molecular Cancer Therapeutics.

[65]  H. Pelicano,et al.  Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells , 2005, Leukemia.

[66]  BinQing Wei,et al.  Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. , 2013, Bioorganic & medicinal chemistry letters.

[67]  E. Giovannetti,et al.  Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia , 2013, British Journal of Cancer.

[68]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[69]  A. Lane,et al.  Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation , 2007, Molecular Cancer Therapeutics.

[70]  M. Todaro,et al.  Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment , 2014, Cell Death and Disease.

[71]  E. Tsiani,et al.  Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. , 2008, Biochemical and biophysical research communications.

[72]  A. Giaccia,et al.  Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents. , 2014, Bioorganic & medicinal chemistry.

[73]  M. Hickey,et al.  Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators. , 2013, Bioorganic & medicinal chemistry letters.

[74]  Qiu-Yun Chen,et al.  Synthesis, cytotoxicity for mimics of catalase: inhibitors of lactate dehydrogenase and hypoxia inducible factor. , 2014, European journal of medicinal chemistry.

[75]  D. Bosco,et al.  Resveratrol Potentiates Glucose-stimulated Insulin Secretion in INS-1E β-Cells and Human Islets through a SIRT1-dependent Mechanism* , 2010, The Journal of Biological Chemistry.

[76]  S. Rosen,et al.  Glucose transporters in cancer metabolism , 2012, Current opinion in oncology.

[77]  Antony E. Fernandes,et al.  Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. , 2013, Bioorganic & medicinal chemistry.

[78]  Jennifer B Dennison,et al.  Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells , 2013, Cancer & Metabolism.

[79]  Anticancer Agents That Counteract Tumor Glycolysis , 2012, ChemMedChem.

[80]  Seong Pil Chung,et al.  D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate , 2011, Cancer Gene Therapy.

[81]  Saroj P. Mathupala,et al.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. , 2009, Seminars in cancer biology.

[82]  Han Xie,et al.  Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. , 2014, Cell metabolism.

[83]  BinQing Wei,et al.  Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. , 2014, Bioorganic & medicinal chemistry letters.

[84]  P. Pedersen,et al.  Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. , 2002, Cancer research.

[85]  T. Clackson,et al.  Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. , 2013, Journal of medicinal chemistry.

[86]  A. Schulze,et al.  Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism , 2013, Cancer & Metabolism.

[87]  J. Guh,et al.  Cryptocaryone, a natural dihydrochalcone, induces apoptosis in human androgen independent prostate cancer cells by death receptor clustering in lipid raft and nonraft compartments. , 2010, The Journal of urology.

[88]  T. Copetti,et al.  Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review , 2011, Front. Pharmacol..